Hennessy Advisors Inc Biogen Inc. Transaction History

Hennessy Advisors Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2022	SELL	$193.77 - $244.14 $1.84 Million - $2.32 Million	-9,500 Closed	0 $0
Q4 2021 Jan 25, 2022	SELL	$223.92 - $287.77 $89,568 - $115,108	-400 Reduced 4.04%	9,500 $2.28 Million
Q3 2021 Oct 12, 2021	SELL	$282.99 - $369.05 $56,598 - $73,810	-200 Reduced 1.98%	9,900 $2.8 Million
Q2 2021 Jul 28, 2021	BUY	$259.0 - $414.71 $51,800 - $82,942	200 Added 2.02%	10,100 $3.5 Million
Q1 2021 Apr 19, 2021	BUY	$242.95 - $284.63 $728,850 - $853,890	3,000 Added 43.48%	9,900 $2.77 Million
Q4 2020 Jan 25, 2021	SELL	$236.26 - $355.63 $70,878 - $106,689	-300 Reduced 4.17%	6,900 $1.69 Million
Q3 2020 Oct 16, 2020	SELL	$264.77 - $305.71 $26,477 - $30,570	-100 Reduced 1.37%	7,200 $2.04 Million
Q2 2020 Jul 20, 2020	SELL	$258.66 - $342.55 $77,598 - $102,765	-300 Reduced 3.95%	7,300 $1.95 Million
Q1 2020 Apr 14, 2020	BUY	$268.85 - $341.04 $2.04 Million - $2.59 Million	7,600 New	7,600 $2.4 Million
Q1 2018 May 02, 2018	SELL	$260.13 - $367.91 $1.95 Million - $2.76 Million	-7,500 Closed	0 $0
Q3 2017 Nov 03, 2017	BUY	$281.15 - $329.69 $2.11 Million - $2.47 Million	7,500	7,500 $2.35 Million

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Hennessy Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Hennessy Advisors Inc with notifications on news.